000			01889na a2200229 4500
003			H12O
005			20180417112602.0
008			130622s2012 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aspa
100			_9576 _aMorales Cerdán, José María _eNefrología
245	0	0	_aAvances en la inmunosupresión para el trasplante renal. Nuevas estrategias para preservar la función renal y reducir el riesgo cardiovascular _h[artículo]
260			_bNefrología, _c2012
300			_a32(3):374-84.
500			_aFormato Vancouver: Bestard O, Campistol JM, Morales JM, Sánchez-Fructuoso A, Cabello M, Cabello V, et al. Advances in immunosuppression for kidney transplantation: new strategies for preserving kidney function and reducing cardiovascular risk. Nefrologia. 2012 May 14;32(3):374-84.
501			_aPMID: 22535159
504			_aContiene 64 referencias
520			_aThe development of new immunosuppressants for renal transplantation is aimed not only at improving short-term outcomes, but also at achieving better safety, cardiovascular, and metabolic profiles and at decreasing nephrotoxicity. Belatacept is a fusion protein that inhibits T cell activation by binding to CD80 and CD86 antigens. Clinical trials, particularly the BENEFIT and BENEFIT-EXT studies, have shown that belatacept preserves function and structure in renal grafts. The effects of belatacept provide long-term, sustained results, and the safety and efficacy of this drug have been demonstrated in cases of renal transplantation from expanded criteria donors. Compared to calcineurin inhibitors, belatacept is associated with a lower incidence of chronic allograft nephropathy and a more favourable cardiovascular and metabolic profile.
710			_986 _aServicio de Nefrología
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/6/pc690.pdf _ySolicitar documento
942			_n0 _2ddc _cART
999			_c690 _d690